Trovafloxacin


w154



General information:


Withdrawn ID: w154
Canonical SMILES:
Standard InChI:
Standard InChIKey:
ATC class(es): J01MA13
Molecular Formula: C20H15F3N4O3
Molweight: 416.36



Withdrawal information:


Withdrawn due to drug safety reasons:Yes
First approved: 1997
First death: 1996
First withdrawn: 1999
Last withdrawn: 1999
Reference: https://www.ncbi.nlm.nih.gov/pubmed/20720197



Side-effects:

Total reported cases (submitted by medical professionals) with Trovafloxacin as primary suspect: 3


Reported final outcomes:
Hospitalization (initial or prolonged): 1
Death: 0


Reported side-effects:

Side-effect Case number
HEPATITIS2
WHITE BLOOD CELL COUNT INCREASED2
HEPATIC FAILURE2
GALLBLADDER DISORDER2
COMA HEPATIC1
COAGULOPATHY1
CONFUSIONAL STATE1
COUGH1
DEHYDRATION1
DEMENTIA1
DIABETES MELLITUS INADEQUATE CONTROL1
DIARRHOEA1
DRUG TOXICITY1
ECTHYMA1
ELECTROCARDIOGRAM T WAVE ABNORMAL1
EPSTEIN-BARR VIRUS ANTIGEN POSITIVE1
FAECAL OCCULT BLOOD POSITIVE1
FATIGUE1
FLUID INTAKE REDUCED1
GANGRENE1
HAEMOGLOBIN INCREASED1
HEART RATE IRREGULAR1
HEPATIC ENCEPHALOPATHY1
HEPATIC FIBROSIS1
HEPATIC NECROSIS1
BLOOD ALBUMIN DECREASED1
ABDOMINAL PAIN1
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED1
ACUTE RESPIRATORY DISTRESS SYNDROME1
AGRANULOCYTOSIS1
ANAEMIA1
ANOREXIA1
ANTIMITOCHONDRIAL ANTIBODY POSITIVE1
ANTINUCLEAR ANTIBODY POSITIVE1
ARTHRALGIA1
ASTHENIA1
ATELECTASIS1
AUTOIMMUNE HEPATITIS1
HEPATITIS ACUTE1
BLOOD PRESSURE DECREASED1
BLOOD SODIUM DECREASED1
BLOOD SODIUM INCREASED1
BLOOD URINE1
BUNDLE BRANCH BLOCK LEFT1
BUNDLE BRANCH BLOCK RIGHT1
CARDIAC ANEURYSM1
CARDIAC MURMUR1
CARDIOMEGALY1
CELLULITIS1
CHEST DISCOMFORT1
SPIDER NAEVUS1
PULMONARY ARTERIAL PRESSURE ABNORMAL1
PULMONARY OEDEMA1
RASH ERYTHEMATOUS1
RED BLOOD CELLS URINE POSITIVE1
RENAL IMPAIRMENT1
SEPSIS1
SERRATIA SEPSIS1
SHOCK1
SKIN BURNING SENSATION1
SKIN DESQUAMATION1
SMALL INTESTINAL OBSTRUCTION1
PROTHROMBIN TIME PROLONGED1
SPLENOMEGALY1
SPUTUM PURULENT1
STREPTOCOCCAL SEROLOGY POSITIVE1
TACHYCARDIA1
TELANGIECTASIA1
UPPER RESPIRATORY TRACT INFECTION1
URTICARIA1
UTERINE LEIOMYOMA1
VENTRICLE RUPTURE1
VERY LOW DENSITY LIPOPROTEIN DECREASED1
WEIGHT DECREASED1
METABOLIC ACIDOSIS1
HEPATOMEGALY1
HEPATOTOXICITY1
HYPOGLYCAEMIA1
HYPOKALAEMIA1
INJURY1
INTERNATIONAL NORMALISED RATIO DECREASED1
INTERNATIONAL NORMALISED RATIO INCREASED1
KETONURIA1
LIVER TRANSPLANT1
LUNG INFILTRATION1
MALAISE1
HEPATOCELLULAR DAMAGE1
MYOCARDIAL INFARCTION1
MYOCARDIAL RUPTURE1
NEUTROPENIA1
PAIN IN EXTREMITY1
PARALYSIS1
PERICARDIAL EFFUSION1
PLEURAL EFFUSION1
PNEUMONIA1
POSTMENOPAUSAL HAEMORRHAGE1
POSTOPERATIVE INFECTION1





Filtered ChEMBL targets:

Target UniProtKB ID Activity in nm Target Name Target gene
P24557 4023 Thromboxane-A synthase THAS_HUMAN



Toxicity information:

Toxicity class: 5
Toxicity type: hepatic
LD50: 2500 mg/kg



External links:

ChEBML: CHEMBL428
DrugBank: DB00685